These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19655338)

  • 1. Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazone.
    Stewart KA; Natzke BM; Williams T; Granger E; Casscells SW; Croghan TW
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1048-52. PubMed ID: 19655338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
    Starner CI; Schafer JA; Heaton AH; Gleason PP
    J Manag Care Pharm; 2008; 14(6):523-31. PubMed ID: 18693776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
    Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program.
    Cluxton RJ; Li Z; Heaton PC; Weiss SR; Zuckerman IH; Moomaw CJ; Hsu VD; Rodriguez EM
    Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):1-9. PubMed ID: 15546159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.
    Stockl KM; Le L; Zhang S; Harada AS
    Pharmacoepidemiol Drug Saf; 2009 Feb; 18(2):166-74. PubMed ID: 19109802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.
    Segal JB; Dy SM; Millman EA; Herbert R; Bass EB; Wu A
    Clin Ther; 2007 Aug; 29(8):1784-94. PubMed ID: 17919559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
    Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
    Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Responding to an FDA warning--geographic variation in the use of rosiglitazone.
    Shah ND; Montori VM; Krumholz HM; Tu K; Alexander GC; Jackevicius CA
    N Engl J Med; 2010 Nov; 363(22):2081-4. PubMed ID: 21083379
    [No Abstract]   [Full Text] [Related]  

  • 9. Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone.
    Leal I; Romio SA; Schuemie M; Oteri A; Sturkenboom M; Trifirò G
    Br J Clin Pharmacol; 2013 Mar; 75(3):861-8. PubMed ID: 22845019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irish Medicines Board safety warnings: do they affect prescribing rates in primary care?
    Musleh S; Kraus S; Bennett K; Zaharan NL
    Pharmacoepidemiol Drug Saf; 2011 Sep; 20(9):979-86. PubMed ID: 21774032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug utilization, safety and clinical use of Actos and Avandia.
    Marks DH
    Int J Risk Saf Med; 2013 Jan; 25(1):39-51. PubMed ID: 23442297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies.
    Noh Y; Kang DR; Kim DJ; Lee KJ; Lee S; Shin S
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1338-1346. PubMed ID: 28771933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Food and Drug Administration warnings on antidepressant use in a national sample.
    Olfson M; Marcus SC; Druss BG
    Arch Gen Psychiatry; 2008 Jan; 65(1):94-101. PubMed ID: 18180433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003-2006.
    Casscells SW; Granger E; Swedorske J; Goldhammer R; Shaheen M; Dorris J; Hong A; Wiktor M
    Am J Ther; 2008; 15(3):198-205. PubMed ID: 18496256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.
    Ruiter R; Visser LE; van Herk-Sukel MP; Geelhoed-Duijvestijn PH; de Bie S; Straus SM; Mol PG; Romio SA; Herings RM; Stricker BH
    Drug Saf; 2012 Jun; 35(6):471-80. PubMed ID: 22540371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical consequences of disseminating the rosiglitazone FDA safety warning.
    Orrico KB; Lin JK; Wei A; Yue H
    Am J Manag Care; 2010 May; 16(5):e111-6. PubMed ID: 20455636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm.
    Shah BR; Juurlink DN; Austin PC; Mamdani MM
    Diabet Med; 2008 Jul; 25(7):871-4. PubMed ID: 18644075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan.
    Hsu JC; Cheng CL; Ross-Degnan D; Wagner AK; Zhang F; Kao Yang YH; Liu LL; Tai HY; Chen KH; Yang PW; Lu CY
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1026-35. PubMed ID: 26251229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings.
    Niyomnaitham S; Page A; La Caze A; Whitfield K; Smith AJ
    BMC Health Serv Res; 2014 Apr; 14():151. PubMed ID: 24708579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of wording in "Dear doctor" letters and in black box labels.
    Weatherby LB; Nordstrom BL; Fife D; Walker AM
    Clin Pharmacol Ther; 2002 Dec; 72(6):735-42. PubMed ID: 12496755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.